Evidence map›Paper›PMID 31407112›Full record

ArticleJournal of cancer research and clinical oncology2019

Meeting report of the 7th Heidelberg Myeloma Workshop: today and tomorrow.

M A Baertsch, R Lutz, M S Raab, N Weinhold, H Goldschmidt

Open access · greenAbstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

M A BaertschHematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany. marc-andrea.baertsch@med.uni-heidelberg.de.ORCID http://orcid.org/0000-0002-4000-6904
R LutzHematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
M S RaabHematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
N WeinholdHematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
H GoldschmidtHematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
Heidelberg University · DEGerman Cancer Research Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe 7th Heidelberg Myeloma Workshop was held on April 5th and 6th, 2019 at the University Hospital Heidelberg. METHODS AND

resultsMain topics of the meeting were (1) diagnostics and prognostic factors, (2) role of immunotherapy in multiple myeloma (MM), (3) current therapy of MM, (4) biology and genomics of MM as well as (5) novel treatment concepts. A debate on the status of minimal residual disease (MRD) driven therapy was held.

conclusionDiagnostics and treatment of newly diagnosed and relapsed MM are continuously evolving. While advances in the field of (single cell) genetic analysis now allow for characterization of the disease at an unprecedented resolution, immunotherapeutic approaches and MRD testing are at the forefront of the current clinical trial landscape.

Indexed as

Disease ManagementHumansMultiple MyelomaImmunotherapyMinimal residual diseaseMultiple myelomaSingle-cell sequencing

Identifiers

PMID31407112
PMCPMC11810335
OpenAlexW2967712966

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.